what is cryptocurrency backed by- Top Featured snippets

SpaceX is valued at about $350 billion due to internal stock sales. According to an email sent to employees seen by the media, SpaceX and its investors have agreed to acquire the company's common stock of up to $1.25 billion at a price of $185 per share. This transaction values the rocket and satellite manufacturer owned by elon musk at about $350 billion. The memo said that the price of $185 per share was much higher than the valuation of $112 less than three months ago. The memorandum was further confirmed by insiders. According to the memo, only SpaceX offered to buy up to $500 million in common stock.The National Southeast Regional Emergency Rescue Center is about to be delivered. It was learned from the recent press conference held in Chaozhou, Guangdong that the National Southeast Regional Emergency Rescue Center is about to be delivered. The National Southeast Regional Emergency Rescue Center is located in Chao 'an District, Chaozhou City, Guangdong Province. It is one of the six national regional emergency rescue centers in China, focusing on the emergency rescue of typhoons and their secondary and derivative disasters. It has basic functions such as emergency command, comprehensive rescue, training drills, equipment storage and transportation, etc., to ensure that it can reach the disaster area in the shortest time to complete the difficult rescue task. (CCTV News)New Zealand appoints WINSTON PETERS as Minister of Railways.

Guotai Junan's annual strategy for innovative drugs in 2025: innovative pharmaceutical companies have accelerated into the harvest period, and the valuation has been at a historical low in the past five years. Guotai Junan said that the centralized purchasing policy has become stable, mature and normalized, and the marginal impact has weakened. Innovative drugs have gained policy inclination in the medical insurance negotiation. In the past two years, the policy has continued to promote pharmaceutical innovation, and the top-level design and local supporting chain support the development of innovative drugs. Commercial insurance is expected to bring new growth momentum to China's pharmaceutical market, and the overall industry trend is upward. At present, the trend of innovative drug industry is improving, the supply continues to accelerate, and a number of domestic innovative drugs are approved soon, which is expected to drive a new round of heavy volume. At the same time, the commercialization has achieved remarkable results and has occupied a dominant position in some sub-sectors. Pharma's performance continued to differentiate, and innovative drugs and just-needed drugs performed well. Biotech commercialization continues to increase, per capita yield continues to increase, the node of turning losses is approaching, and innovation ushers in the harvest period. Horizontal comparison: compared with overseas peers, the overall valuation of domestic innovative pharmaceutical companies is in a historically low range; Vertical comparison: the valuation of SW- pharmaceutical biology and SW- chemical preparations is at a historical low in the past five years, and it is expected that the valuation of subsequent sectors will pick up.South Korea's exports increased by 12.4% and imports increased by 11.6% from December 1 to 10. South Korea's chip exports increased by 43% year-on-year from December 1 to 10.Guotai Junan's annual strategy for innovative drugs in 2025: innovative pharmaceutical companies have accelerated into the harvest period, and the valuation has been at a historical low in the past five years. Guotai Junan said that the centralized purchasing policy has become stable, mature and normalized, and the marginal impact has weakened. Innovative drugs have gained policy inclination in the medical insurance negotiation. In the past two years, the policy has continued to promote pharmaceutical innovation, and the top-level design and local supporting chain support the development of innovative drugs. Commercial insurance is expected to bring new growth momentum to China's pharmaceutical market, and the overall industry trend is upward. At present, the trend of innovative drug industry is improving, the supply continues to accelerate, and a number of domestic innovative drugs are approved soon, which is expected to drive a new round of heavy volume. At the same time, the commercialization has achieved remarkable results and has occupied a dominant position in some sub-sectors. Pharma's performance continued to differentiate, and innovative drugs and just-needed drugs performed well. Biotech commercialization continues to increase, per capita yield continues to increase, the node of turning losses is approaching, and innovation ushers in the harvest period. Horizontal comparison: compared with overseas peers, the overall valuation of domestic innovative pharmaceutical companies is in a historically low range; Vertical comparison: the valuation of SW- pharmaceutical biology and SW- chemical preparations is at a historical low in the past five years, and it is expected that the valuation of subsequent sectors will pick up.

Google asked the US Federal Trade Commission (FTC) to terminate the exclusive cloud service agreement between Microsoft and OpenAI.Eight people were killed when the Israeli army attacked a house in the central part of Gaza, and eight people were killed and many others were injured when the Israeli army bombed a house in Nuseilet refugee camp in the central part of Gaza on the evening of 10th local time.Galaxy Securities: Macro-policies have increased the accumulation of positive factors in bank fundamentals. The china galaxy Securities Research Report said that the macro-policy upgrade has exceeded expectations and supported the growth of bank credit. Bank spreads are still under pressure, but the release of debt cost optimization results is expected to form support. Preventing and resolving the risk orientation in key areas remains unchanged, and the asset quality and risk expectation of banks are expected to benefit. The positive factors in the fundamentals of banking operations have accumulated, and we will continue to be optimistic about the allocation value of the banking sector and maintain the recommended rating. For individual stocks, ICBC, China Construction Bank, Postal Savings Bank, Jiangsu Bank and Changshu Bank are recommended.